Unleashing cell-penetrating peptide applications for immunotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koo, Ja-Hyun | - |
dc.contributor.author | Kim, Gil-Ran | - |
dc.contributor.author | Nam, Kyung-Ho | - |
dc.contributor.author | Choi, Je-Min | - |
dc.date.accessioned | 2022-07-19T04:56:25Z | - |
dc.date.available | 2022-07-19T04:56:25Z | - |
dc.date.created | 2022-06-03 | - |
dc.date.issued | 2022-06 | - |
dc.identifier.issn | 1471-4914 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/170102 | - |
dc.description.abstract | With the advent of cancer immunotherapy, immunomodulation has emerged as an important strategy for the treatment of various diseases. We review recent advances in clinical trials of cell-penetrating peptide (CPP) applications for immunotherapy and also discuss their challenges and opportunities for preclinical studies in various immune diseases. CPP conjugation to antigenic peptides or proteins can enable efficient antigen uptake and cross-presentation by antigen-presenting cells (APCs), which induce both humoral and cytotoxic responses. In addition, CPP-coupled immune modulators can enhance antitumor immunity or anti-inflammatory effects to regulate allergies and autoimmunity. Given their huge advantages in overcoming delivery barriers, CPP-based strategies for immunomodulation could extend drug optimization and advance immunotherapy in various human diseases. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Elsevier Ltd | - |
dc.title | Unleashing cell-penetrating peptide applications for immunotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Je-Min | - |
dc.identifier.doi | 10.1016/j.molmed.2022.03.010 | - |
dc.identifier.scopusid | 2-s2.0-85129887151 | - |
dc.identifier.wosid | 000807273800006 | - |
dc.identifier.bibliographicCitation | Trends in Molecular Medicine, v.28, no.6, pp.482 - 496 | - |
dc.relation.isPartOf | Trends in Molecular Medicine | - |
dc.citation.title | Trends in Molecular Medicine | - |
dc.citation.volume | 28 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 482 | - |
dc.citation.endPage | 496 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Cell Biology | - |
dc.relation.journalResearchArea | Research & Experimental Medicine | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Cell Biology | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.subject.keywordPlus | PROTEIN-KINASE-C | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | NANOPARTICLE DELIVERY | - |
dc.subject.keywordPlus | CYTOPLASMIC DOMAIN | - |
dc.subject.keywordPlus | P53 UBIQUITINATION | - |
dc.subject.keywordPlus | ATOPIC-DERMATITIS | - |
dc.subject.keywordPlus | CYCLOSPORINE-A | - |
dc.subject.keywordPlus | TOPICAL GEL | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1471491422000788?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.